Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 2/20 | 0.31 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30210548 | 0.70 | GAA (0.33) | — | |
| SCHEMBL23349325 | 0.69 | — | — | |
| SCHEMBL2664632 | 0.68 | SCD (0.36) | ADRA1AADRA1D | |
| SCHEMBL999429 | 0.67 | ADRA1A (0.32) | ADRA1AADRA1D | |
| SCHEMBL23065253 | 0.65 | ADRA1D (0.31) | ADRA1AADRA1D | |
| SCHEMBL19546734 | 0.65 | BRD4 (0.43) | — | |
| SCHEMBL13298015 | 0.65 | BRD4 (0.43) | — | |
| SCHEMBL19546202 | 0.65 | BRD4 (0.43) | — | |
| SCHEMBL14544573 | 0.65 | BRD4 (0.43) | — | |
| SCHEMBL124340 | 0.65 | BRD4 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100063023-A1 | Bicyclic and Tricyclic Substituted 6-Methylidene Carbapenems as Broad Spectrum Beta-Lactamase Inhibitors | WYETH (US) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063023-A1 | Bicyclic and Tricyclic Substituted 6-Methylidene Carbapenems as Broad Spectrum Beta-Lactamase Inhibitors | MGAM, CYP2C18, BCAT2 | ADRA1A 2487/4885ADRA1D 1944/4885HRH1 1794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.